What you need to know about Johnson & Johnson’s approved single-dose vaccine
Canada added a single-dose COVID-19 vaccine to its pandemic-fighting arsenal on Friday, approving Johnson & Johnson’s product a week after it was authorized in the United States.
That gives Canada four distinct vaccines — along with Pfizer-BioNTech, Moderna and Oxford-AstraZeneca — and it adds flexibility to the country’s plan to immunize the majority of its residents by September. Health Canada includes a fifth vaccine, Covishield, which is a separate brand name for doses of the AstraZeneca product made at the Serum Institute of India.
The U.S.-based Food and Drug Administration (FDA) approved the Johnson & Johnson vaccine for emergency use on Feb. 27.
Canada has already secured 10 million doses of the Johnson & Johnson vaccine through previous negotiations with the company, with the option to buy another 28 million. The 10 million pre-purchased doses will be delivered before September, but they’re not expected to start flowing into Canada until at least April.


